The Food and Drug Administration granted Fast Track designation to Dyax
Corp. (Nasdaq: DYAX) for DX-2930 for the prevention of hereditary angioedema
attacks after the company reported positive Phase 1b study results. The stock price leaped $7.98 to $24.73.
Fast Track designation granted to Dyax for DX-2930
April 01, 2015 at 13:29 PM EDT
